

1 **Idiopathic subglottic stenosis arises at the interface of host and pathogen.**

2
3 Alexander Gelbard¹, Meghan H. Shilts², Britton Strickland³, Kevin Motz⁵, Hsiu-Wen Tsai⁵, Helen
4 Boone², Wonder P. Drake³, Celestine Wanjalla³, Paula Marincola Smith⁶, Hunter Brown²,
5 Marisol Ramirez⁸, James B. Atkinson⁴, Jason Powell^{7, 8}, A John Simpson^{7, 8}, Seesandra V.
6 Rajagopala², Simon Mallal^{2, 3}, Quanhui Sheng⁹, Alexander T. Hillel⁵, Suman R. Das^{2, 3}

7
8 ¹Department of Otolaryngology-Head & Neck Surgery, Vanderbilt University Medical Center,
9 Nashville, TN.

10 ²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

11 ³Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, TN.

12 ⁴Department of Pathology Microbiology and immunology, Vanderbilt University Medical Center,
13 Nashville, TN.

14 ⁵Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins, Baltimore, MD.

15 ⁶Department of Surgery, Vanderbilt University Medical Center, Nashville, TN.

16 ⁷Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

17 ⁸The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

18 ⁹Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.

19

20 **#Corresponding authors:**

21 Dr. Suman R. Das, Ph.D.

22 Division of Infectious Diseases

23 Department of Medicine

24 Vanderbilt University Medical Center

25 1211 21st Avenue South

26 S2108 Medical Center North

27 Nashville, TN 37232

28 E-Mail: suman.r.das@vumc.org

29 Phone: 615-322-2419

30

31 Alexander Gelbard

32 Department of Otolaryngology-Head & Neck Surgery

33 Vanderbilt University Medical Center

34 1211 21st Avenue South

35 S2108 Medical Center North

36 Nashville, TN 37232

37 E-Mail: alexander.gelbard@vumc.org

38 Phone: 615-343-7464

39 **ABSTRACT**

40 Idiopathic subglottic stenosis (iSGS) is a rare fibrotic disease of the proximal airway
41 affecting adult Caucasian women nearly exclusively. Life-threatening ventilatory obstruction
42 occurs secondary to pernicious subglottic mucosal scar. Diverse diseases in divergent organ
43 systems are associated with fibrosis, suggesting common biologic mechanisms. One well
44 characterized pathway is chronic inflammation secondary to pathogen. In the present study, we
45 explored the role of the proximal airway microbiome in iSGS pathogenesis. In human samples,
46 abundant bacteria are detectable in iSGS scar as well as in health subglottic controls or patients
47 that developed subglottic stenosis following endotracheal intubation. Interestingly, the community
48 structure of the iSGS proximal airway microbiome does not appear disrupted. Rather, in iSGS
49 defects in the airway epithelial barrier allow displacement of the native microbiome into the
50 immunoprivileged lamina propria and are associated with adaptive immune activation. Animal
51 models of iSGS confirm both bacteria and an adaptive immune response are necessary for
52 pathologic proximal airway fibrosis. Single cell RNA sequencing of the affected airway in iSGS
53 offers an unbiased characterization of the observed epithelial barrier dysfunction. The airway scar
54 in iSGS patients demonstrates basal cell depletion and epithelial acquisition of a mesenchymal
55 phenotype. The epithelial alterations are associated with the observed microbiome displacement,
56 dysregulated immune activation, and localized fibrosis. These results refine our understanding
57 of iSGS and implicate shared pathogenic mechanisms with distal airway fibrotic diseases.

58 INTRODUCTION

59 Idiopathic subglottic stenosis (iSGS) is a rare(1) but devastating fibroinflammatory airway
60 disease that occurs almost exclusively in adult, Caucasian women(2). The disease is
61 characterized by mucosal inflammation and localized fibrosis resulting in life-threatening blockage
62 of the upper airway(3). Current treatments are limited by high recurrence rates, and the majority
63 of iSGS patients require frequent procedural interventions following their initial diagnosis(4).
64 Given the significant emotional, physical, and financial costs associated with recurrent airway
65 obstruction(5), most research efforts have focused on procedural techniques to improve airway
66 patency(6). However, highly focused scientific approaches to identify key elements of iSGS
67 disease pathophysiology are essential to developing less invasive and more durable treatments.

68 Histologically, iSGS cases show a pronounced immune infiltrate and mucosal fibrosis(7).
69 Diverse diseases in divergent organ systems are associated with fibrosis, suggesting common
70 biologic triggers. One of the most well-characterized triggers is chronic inflammation secondary
71 to pathogen(8). Investigations in alternate pulmonary pathologies have associated alterations in
72 the airway microbiome with tissue remodeling in cystic fibrosis(9), and disease progression in
73 pulmonary fibrosis(10). Recent data suggest iSGS may share these pathogenic mechanisms with
74 lower airway fibrotic diseases. Chronic inflammation in airway scar(11) and bacteria in superficial
75 mucosal swabs(12) provide preliminary support to the hypothesis that an aberrant immune
76 response directed against bacterial species participate in the airway fibrosis in iSGS.

77 In the present study, we interrogated the relationship between microbial species and iSGS
78 disease. We show abundant bacteria in iSGS scar with a community structure indistinguishable
79 from controls. Interestingly, in iSGS the native microbiome appears displaced into the
80 immunoprivileged lamina propria and is associated with significant immune infiltration. Unbiased
81 molecular interrogation of iSGS airway scar with single cell RNA sequencing confirmed barrier
82 dysfunction characterized by basal progenitor loss and residual epithelial acquisition of a
83 mesenchymal phenotype. Animal models confirmed an essential role for both bacteria and an

84 adaptive immune response to tissue remodeling after mucosal injury. Our data suggests that in
85 iSGS the native microbiome is displaced across a dysfunctional epithelial barrier into the
86 immunoprivileged lamina propria driving an adaptive immune response specific for native
87 bacterial species. These results refine our understanding of iSGS, implicate shared pathogenic
88 mechanisms with distal airway fibrotic diseases, and open new avenues for therapy.

89 RESULTS

90 ***Characterization of mucosal microbiome in iSGS***

91 iSGS patients possess obstructive mucosal scar in the proximal airway distal to the vocal cords
92 (**Figure 1A**). Study patients were diagnosed according to standard clinical criteria(2) and
93 described in supplemental Table 1. We first quantified the number of 16S rRNA gene copies in
94 deep tissue biopsies via qPCR (**Figure 1B**) and detected consistent signal in both iSGS patients
95 and disease controls (patients that developed subglottic stenosis following prolonged intubation:
96 iLTS). iLTS patients had a significantly higher bacterial load compared to iSGS samples (mean
97 iSGS copy number: 520,000 vs iLTS: 1,370,000; $P < 0.0001$). We then performed 16S rRNA
98 sequencing for insight into bacterial community structure. For further analysis, 37/50 (74%) iSGS
99 and 18/27 (67%) iLTS samples were retained after implementing a cutoff of 500 high-quality 16S
100 reads (2 standard deviations above the maximum number of reads in any of the negative
101 controls).

102
103 The top 20 most abundant bacterial families and genera are shown per each sample for iSGS,
104 iLTS and healthy subglottic controls (**Supplemental Figure 1**). The majority of bacterial species
105 present in healthy subglottis were consistent with the established healthy lung microbiome
106 composed of supraglottic predominant taxa (e.g. *Prevotella*, *Streptococcus*)(13). Using principal
107 coordinates analysis (PCoA), we compared the overall microbial community structure between
108 iSGS, iLTS, and healthy subglottic controls. As seen in **Figure 1C**, there was no significant
109 differences in the centroids between the three groups (PerMANOVA adonis2 testing $p = 0.06$). To
110 validate these findings, we next utilized Bray-Curtis dissimilarities to make binary comparisons
111 between only healthy and iLTS samples, and between only healthy and iSGS samples. iSGS
112 samples more closely resembled healthy controls than iLTS samples resembled healthy
113 subglottic controls (Wilcoxon rank sum test with continuity correction, $p\text{-value} = 0.001$ **Figure 1D**).

114

115 Additional testing of microbial community structure using established indices for diversity and
116 richness confirmed no detectable differences between iSGS, iLTS and healthy controls. ANOVA
117 testing of alpha diversity (mean Shannon index - iSGS: 15.28 vs iLTS: 14.53 vs healthy controls;
118 $p=0.39$, mean Simpson index - iSGS: 15.28 vs iLTS: 14.53 vs healthy controls; $p=0.822$) and
119 richness (mean Chao1 index - iSGS: 40.75 vs iLTS: 40.45; vs. healthy controls, $p=0.082$, **Figure**
120 **1E**) showed no significant differences. Additionally, there was not a significant association
121 between iSGS disease severity and overall bacterial load ($p = 0.36$, **Supplemental Figure 2A**)
122 nor between disease severity and alpha diversity ($p = 0.453$, **Supplemental Figure 2B**) or
123 richness (p -value = 0.6078, data not shown).

124

125 ***Anatomic location of bacterial species in iSGS mucosal scar***

126 To validate our findings and explore if superficial and deep tissue sampling methods produced
127 unique bacterial communities, we next compared published 16S rRNA sequencing data of
128 superficial swabs of iSGS scar ($n=5$)(12) with our deep tissue biopsies (**Figure 2A**). The top 20
129 most abundant genera were highly concordant between the superficial and deep sampling
130 methods, despite differences in patient populations and lab processing protocols; offering support
131 for our findings (the one significantly different genus was *Halomonas* which was abundant in swab
132 samples and absent in tissue).

133

134 Because 16S sequencing of the superficial and deep microbiome appeared identical, we
135 investigated if native bacterial displacement into the deeper lamina propria was a unique feature
136 of iSGS. Employing fluorescence in situ hybridization (FISH) with the pan-bacterial probe,
137 Eub338, we investigated if mucosal biopsies from iSGS and healthy controls evidenced bacteria
138 in the deep layers of the proximal airway mucosa. Representative FISH stains show iSGS mucosa
139 possessed signal for bacteria in the deeper lamina propria while healthy control did not (**Figure**
140 **2B**). In a separate biopsy derived from iSGS mucosal scar, transmission electron microscopy

141 demonstrated numerous forms consistent with the size and shape of bacteria in the cell
142 cytoplasm, supporting the FISH staining (**Figure 2C**).

143

144 ***Both bacteria and adaptive immunity are necessary for mucosal scar after epithelial injury.***

145 We next employed an established murine model of subglottic stenosis(14) to investigate the roles
146 of bacteria and adaptive immunity in the mucosal fibrosis that characterizes iSGS. As expected,
147 wild type mice developed mucosal inflammation and significant thickening of the lamina propria
148 14 days after injury (WT injury vs WT sham: 81 μ m +/- 37 vs. 24 μ m +/- 4, p=0.0036). Interestingly
149 however, no significant thickening of the lamina propria was observed when using either germ
150 free mice (GF injury vs GF sham: 46 μ m +/- 9.4 vs. 27 +/- 11, p=0.56), or severe combined
151 immunodeficient mice (SCID)(15) lacking an adaptive immune response (SCID injury vs SCID
152 sham: 41 μ m +/- 11 vs. 34 +/- 11, p=0.98). WT injury was significantly greater than both GF injury
153 (p=0.025) and SCID injury (p=0.036) (**Figures 2D & E**).

154

155 ***Single cell sequencing of subglottic mucosal scar in iSGS reveals epithelial cell loss and***
156 ***a pronounced immune cell infiltrate compared to unaffected mucosa.***

157 To determine the distribution and phenotype of the cellular populations present in iSGS airway
158 scar, we generated single-cell suspensions from tissue biopsies of both airway scar (n=7) and
159 matched unaffected airway mucosa (n=3) (Supplemental Table T2) and performed scRNAseq
160 using the 10x Genomics Chromium platform (see supplementary Materials and Methods). The
161 samples were collected and processed at two different sites (Supplemental Table T3); however,
162 both sites collected cases and controls. In an effort to maximize our ability to identify rare cell
163 populations, we jointly analyzed data from all samples. We defined inclusion criteria for cells
164 based on observations from the entire dataset, removed low-quality cells accordingly, applied
165 normalization and variance stabilization of the 25,974 recovered cells using Seurat(16, 17),
166 integrated the data using the harmony(18), performed unsupervised clustering using Seurat, and

167 classified the cell type of each cluster based on PanglaoDB(19) followed by manual annotation
168 based on canonical markers to annotate clusters. We defined 22 cell types/states in the subglottis
169 (initially one small CD8 effector T cell population was grouped together with a larger CD8 T
170 effector population due to observations that cell cycle activity was driving distinct cluster identity).
171 All cell types were identified both in airway scar and healthy mucosa. Notably, we did not observe
172 overt batch effects driven by processing site or sequencing batch in our dimensionality reduction
173 and visualization (Supplemental Figure S4). Cell types/states were also manually grouped into 4
174 broad tissue classes (Immune/Epithelial/Endothelial/Mesenchymal) based on their identity
175 (**Figure 3A**), and confirmed with canonical lineage markers (**Supplemental Figure S5**).
176 Quantification of cell types demonstrated significant differences between iSGS airway scar and
177 matched healthy mucosa controls. Airway scar showed significantly more Immune cells (cell
178 count per 1000 cells: scar vs healthy control: 636 vs. 238, $P = 0.018$) and significantly fewer
179 epithelial cells (scar vs healthy control: 155 vs. 685, $P < 0.001$) (**Figure 3B**). The molecular results
180 were confirmed at the protein level with flow cytometry (**Supplemental Figure S7**).

181
182 In addition to quantitative differences in cell types/states, we compared phenotypic alterations
183 between scar and healthy mucosa by examining the number of differentially expressed genes
184 using EdgeR(20) (DEG: $P < 0.05$, log fold change $> |1.5|$) (**Figure 3C**). This analysis demonstrated
185 wide variability across the cell types, with epithelial cells and fibroblasts showing the greatest
186 number of DEG (**Supplemental Figure S8**). When grouping cells into their tissue layer, the
187 epithelium demonstrated significantly more DEG than immune cells (mean number of genes $P <$
188 0.05 and fold change $> |1.5|$, Epithelium = 252 vs 11 in immune, $P = 0.007$). The difference
189 between epithelial cells and fibroblasts or endothelium was not significant. These results suggest
190 that in addition to a quantitative reduction in cell numbers, the residual epithelium in iSGS scar is
191 also phenotypically distinct.

192

193 ***Molecular profiling of epithelium in iSGS scar reveals significantly reduced basal***
194 ***populations and enrichment for a molecular program of epithelial mesenchymal transition.***

195 We further analyzed the epithelial clusters (**Figure 3D**) and identified conserved transcriptional
196 programs in basal (four clusters), ciliated (three clusters), secretory (one cluster), and a
197 proliferating cell subset (one cluster). Based on our observation of differential cluster abundance
198 between scar and healthy mucosa (**Figure 3E**), we quantified the number of cell types/states from
199 both scar and healthy mucosa. The clusters comprising basal, secretory, and ciliated cells showed
200 significant reductions in scar samples (Boxes depict median and interquartile range, whiskers
201 show min to max, *P < 0.05 by Mann-Whitney U. ; **Figure 3F**). In addition to the dramatic loss of
202 basal cells within airway scar, geneset enrichment analysis demonstrated that residual
203 proliferating epithelial cells expressed a molecular program for epithelial mesenchymal transition
204 (EMT) (**Figure 3G**). Additional upregulated genesets included oxidative phosphorylation and
205 mTOR signaling consistent with observed proliferation markers Protein Phosphatase 1,
206 Regulatory Subunit 105 (Ki67) and Cyclin Dependent Kinase 1 (CDK1) (**Supplemental Figure**
207 **S5**). Gene ontology (GO) pathway analysis supported the Hallmark geneset EMT findings; iSGS
208 airway scar showed enrichment for mitochondrial matrix genes (along with aerobic respiration
209 and electron transfer activity). In parallel, proliferating epithelial cells in iSGS airway scar showed
210 down-regulated glycosylation and junctional protein complexes (both apical and tight). Both
211 aerobic respiration and loss of cell-cell adhesion are consistent with EMT.

212

213 ***iSGS scar demonstrates increased adaptive immune cell subsets.***

214 Next, to explore the constituents of the immune cell infiltrate seen in iSGS airway scar (**Figure**
215 **4A**), we compared the cell types observed in scar with unaffected mucosa (**Figure 4B**).
216 Quantification of cell types demonstrated significantly greater CD8 T_{eff} cells in scar (scar vs.
217 healthy: 167+/-103 vs. 34+/-26, P=0.033), along with more CD4+ T_{reg} (scar vs healthy: 37+/-15 vs.
218 4+/-3 P=0.005) and more NK cluster 2 cells (scar vs. healthy: 57+/-54 vs. 5+/-5, P=0.025). In

219 contrast, the NK cluster 1 population was significantly reduced in scar (scar vs healthy: 4+/-9 vs.
220 36+/-37) (**Figure 4C**).

221

222 ***The native proximal airway microbiome generates an antigen-specific immune response***
223 ***in infiltrating CD4+ and CD8+ T cells.***

224 In order to probe the function of the observed immune infiltrate, tissue biopsies acquired during
225 operative endoscopy of 5 unique iSGS patients were used to create fresh single cell suspensions
226 as described. Suspensions were rested for 6 hours, then cultured in the presence of a matched
227 iSGS airway microbiome, the microbiome from an unrelated healthy subject, or left untreated.
228 After 24 hours of stimulation, cells were washed and stained for markers of T cell activation
229 (CD154) and analyzed via flow cytometry (**Figure 4D**). For CD4+ and CD8+ T cells, both the
230 matched iSGS microbiome, as well as the microbiome from an unrelated healthy control
231 significantly upregulated CD154 when compared to untreated experimental controls (CD4+
232 matched iSGS microbiome vs untreated: 3741 +/-1934, vs. 2912 +/- 1958, p=0.007; CD4+
233 unrelated healthy microbiome vs untreated: 3641+/- 2287 vs. 2912 +/- 1958, p=0.04), (CD8+
234 matched iSGS microbiome vs untreated: 3943 +/- 1989 vs. 2845 +/- 2098, p=0.005; CD8+
235 unrelated healthy microbiome vs untreated: 3784 +/- 1768 vs. 2845 +/- 2098, p=0.03) (**Figure**
236 **4E**). For both CD4+ and CD8+ T cells, CD154 expression was not significantly different between
237 cells treated with a matched iSGS microbiome or cells treated with an unrelated healthy
238 microbiome. These data suggest that while the native airway microbiome can trigger an antigen-
239 specific immune response in iSGS, T cell activation in iSGS mucosal scar can also occur when
240 presented with the bacterial constituents of a healthy individual.

241 **DISCUSSION**

242 Idiopathic subglottic stenosis (iSGS) is a debilitating localized fibrosis of the proximal
243 airway. Affected patients possess tightly conserved clinical demographics, histopathology, and
244 physiologic impairment(4). Our data suggest that defects in epithelial barrier function can allow
245 displacement of the native microbial community deep into the airway mucosa and contribute to
246 dysregulated immune activation leading to fibrotic remodeling in iSGS. Our animal models reveal
247 that both bacteria and an intact adaptive immune response are necessary to drive tissue
248 remodeling after proximal airway epithelial injury.

249 The pseudostratified epithelium lining the human airway is comprised of a number of
250 distinct populations of cells with specialized effector functions. Airway epithelium and the overlying
251 mucocilliary layer maintain a physical barrier against environmental insults (pathogens, allergens,
252 and toxins). Many primary respiratory diseases, including chronic obstructive pulmonary disease
253 (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) display substantial pathological
254 alterations in the airway epithelium. Evidence suggests impairment of the epithelial immune
255 barrier allows bacteria to penetrate the airway surface liquid, intercalate within the epithelium, and
256 activate host immunity. This inflammation, when sustained inappropriately, can culminate in
257 fibrotic tissue remodeling and physiologic impairment.

258 In COPD secondary to cigarette exposure, respiratory mucosal inflammation and fibrotic
259 remodeling contribute to small airway obstruction and clinical symptoms(21). Yet even after
260 smoking cessation, many patients with COPD have sustained inflammation and disease
261 progression(22). Published data in COPD demonstrate this persistent epithelial dysfunction (even
262 after cessation of the inciting toxic insult) results from impaired immunbarrier protection.
263 Dysfunctional epithelium leads to bacterial invasion deep into the mucosa and fibrotic airway
264 remodeling(23). Animal models suggest that endogenous bacteria orchestrate a persistent and
265 pathologic adaptive immune response that drives tissue remodeling(24).

266 Similarly, asthma is characterized by airway inflammation and tissue remodeling in
267 response to antigenic trigger (25). In asthmatics, the epithelial barrier loses differentiation, and
268 junctional integrity is impaired. Epithelial dysfunction appears to be a central driver of atopy, as
269 it frequently pre-dates the development of allergic symptoms(26). In IPF, animal models, *in vitro*
270 human data and genetic evidence suggest that the airway epithelium plays a central role in
271 disease susceptibility and initiation(27). It is hypothesized that repetitive, small injuries to
272 vulnerable alveolar epithelial cells result in apoptosis and impaired re-epithelialization, while
273 epithelial-mesenchymal interactions drive subsequent extracellular matrix expansion(28).

274 Beyond the central role airway epithelial cells play in human respiratory disease,
275 numerous studies have shown a specific role for the basal cell subset in repair and regeneration
276 of the respiratory system after epithelial injury(29-31). Fate-mapped mouse strains have shown
277 that basal cells contribute to regeneration of the pulmonary parenchyma in response to both
278 chemical(32) and viral injury(33). Murine models of chemical-induced epithelial injury have shown
279 that severe mucosal destruction involving the basal cell layer is associated with an uncontrolled
280 proliferation of the underlying stroma, resulting in an accumulation of fibroblasts and immune cells
281 that subsequently obliterate the airway lumen(34). The reduction of basal cell subsets we
282 observed in our data may partially explain the discorded tissue remodeling seen clinically in
283 iSGS(7, 35).

284 Interestingly, in addition to the observed basal cell depletion in iSGS airway scar, geneset
285 enrichment analysis (GSEA) of the residual epithelial cells showed mechanistic target of
286 rapamycin (mTORC1) pathway activation and enhanced aerobic metabolism. mTOR is a master
287 sensor that integrates environmental factors to regulate cell growth. In general, activation of
288 mTOR stimulates proliferation, mitochondrial biogenesis and oxidative phosphorylation(36). The
289 GSEA findings were consistent with the observed KI67 and CDK1 expression (marking cellular
290 proliferation) in the epithelium of iSGS airway scar. Additionally GSEA showed the residual
291 epithelium in iSGS airway scar acquired a mesenchymal phenotype with epithelial-mesenchymal

292 transition (EMT) pathway enrichment. EMT allows disassembly of cell-cell junctions, actin
293 cytoskeleton reorganization and induction of contractile proteins as non-motile epithelial surfaces
294 convert into individual, a motile mesenchymal phenotypic. These phenotypic alterations may
295 result from localized pathogen-driven inflammation(37) or can result from mucosal injury
296 secondary to physiologically relevant bile acid exposure(38). Integrating the basal cell depletion
297 with GSEA findings supports the hypothesis that mucosal barrier dysfunction participates in iSGS
298 disease pathogenesis.

299 Although an often overlooked anatomic subsite, the subglottis is uniquely enriched in
300 antigen-presenting dendritic cells as well as T lymphocytes (39, 40). Additionally, it functions as
301 a transition zone from the ciliated lining of the trachea to the squamous epithelium of the larynx.
302 As a consequence, the subglottis has increased exposure to pathogens as the cilia-driven upward
303 movement of the airway mucus layer temporarily stalls(41). While the inciting event for barrier
304 dysfunction in iSGS is unclear, both genetic predisposition and environmental insults can impair
305 epithelial function. Although the genetic foundations of iSGS remain obscure(42), many candidate
306 susceptibility genes identified via GWAS for Asthma(43) and COPD(44) suggest a role for
307 epithelial damage and adaptive immune activation in disease pathogenesis. Similarly, validated
308 susceptibility genes for IPF(45) frequently impact epithelial integrity(46). Alternatively, allergens
309 are capable of disrupting physical integrity of the barrier via their protease activity, while several
310 respiratory viruses specifically target junctional proteins in the airway epithelium leading to barrier
311 dysfunction (26) and adaptive immune activation(47).

312 Prior small case series examining environmental factors contributing to iSGS have
313 implicated disruption of the proximal airway microbiome, one using pathogen-specific molecular
314 approaches(48), and another employing 16S rRNA sequencing of mucosal swabs(12). While
315 these studies implicated the presence of microbial species in iSGS, our new data from a larger,
316 and more diverse patient cohort provides an unbiased characterization of the mucosal tissue
317 microbiome. Our current results suggest that rather than microbiome disruption, in iSGS a

318 “healthy microbiome” is displaced across a dysfunctional epithelium. This displacement is
319 associated with adaptive immune infiltration and activation in response to bacterial species. This
320 is supported by the finding that both a matched host microbiome, as well as the microbiome from
321 a healthy control can drive adaptive immune activation in the proximal airway scar.

322 However, the displaced microbiome may not be the sole target of the adaptive immune
323 response observed in iSGS mucosal scar. A feed-forward inflammatory loop may become
324 established when peptides from microbial proteins share sufficient structural similarity with self-
325 peptides and activate autoreactive T cells, termed “molecular mimicry”(49). Inflammation resulting
326 from bacterial infection can also activate local antigen-presenting cells and enhance processing
327 and presentation of self-antigens, referred to as “epitope spreading”. Sustained innate immune
328 activation in response to pathogen specific molecular patterns (PAMPs) may also participate in
329 the observe localized mucosal inflammation in iSGS and potentiate epithelial damage.

330 Although we acknowledge the limited ability to assign causality in pathologic studies
331 involving human tissue, combining bacterial profiling along with histologic localization, animal
332 models and *in vitro* techniques provided consistent support to our hypothesis. Despite the inherent
333 limits involved in rare disease research, our translational approach offers new insights into
334 disease pathogenesis. Additionally, deconstructing the proximal airway tissue into its component
335 cells based on transcriptional data derived from single cell RNA sequencing provides an unbiased
336 view into the cellular ecosystem of human idiopathic subglottic stenosis, helping us to characterize
337 the phenotype, major cell types in airway scar without the biases that are typically introduced by
338 pre-selection of markers. Complementing this molecular data, our functional studies support the
339 concept that defects in epithelial barrier function allow translocation of the native microbial
340 community deep into the airway mucosa and drive dysregulated immune activation leading to
341 fibrotic remodeling in iSGS. Animal models reveal that both bacterial and an intact adaptive
342 immune response are necessary to drive tissue remodeling after proximal airway epithelial injury.

343 Our findings dramatically shift our concept of iSGS disease pathogenesis and implicate
344 shared pathogenic mechanisms with distal airway fibrotic diseases. Most critically, these results
345 suggest that proven treatment approaches pioneered in pulmonary fibrosis may provide
346 therapeutic benefit in iSGS and warrant rigorous future study.

347 **METHODS**

348 Detailed experimental methods are included in the Supplemental Material.

349 The accession number for the 16S sequencing data reported in this paper Bioproject number
350 PRJNA784956, and the accession number for the single cell RNA-sequencing data is
351 GSE191128.

352

353 **STUDY APPROVAL**

354 Patients in this study with subglottic stenosis provided written and informed consent to tissue
355 collection under a Vanderbilt University Medical Center institutional review board (IRB)-approved
356 protocol (no. 140429). Healthy subglottic controls were obtained under UK Research Ethics
357 Committee (no. 14/SS/1015 & 15/WM/0349). Human experiments at Johns Hopkins University
358 were performed under IRB-approved protocol (no. NA_00078310). For murine experiments, all
359 mice were housed and bred at Johns Hopkins in accordance with the regulatory standards of the
360 National Institutes of Health (NIH) and American Association of Laboratory Animal Care standards
361 and were consistent with the Johns Hopkins Institution of Animal Care and Use Committee (no.
362 MO18M124).

363

364

365 **AUTHOR CONTRIBUTIONS**

366 B.S., H.B., H.B., J.P. and J.S. performed 16S sequencing experiments. S.D. S.R. and M.S.
367 conducted microbiome analysis. A.H., H.T. and K.M. performed murine experiments. P.M.
368 performed FISH assay. A.G. and C.W. participated in preparation and analysis in vitro T cell
369 activation assays. A.G., M.R. and Q.S. processed and analyzed RNA-seq data. A.G. designed
370 the experiments and wrote the manuscript. W.D. and S.M. provided critical review of experimental
371 design and performed data analysis.

372

373 **ACKNOWLEDGEMENTS**

374 This work was supported in part by the NIH/NHLBI grant no. R01HL146401 (A.G.).

375 Patient-Centered Outcomes Research Institute award number: 1409-22214 (A.G.).

376 **FIGURE LEGENDS**

377 **Figure 1.** Microbial Speices in iSGS airway Scar. (A) Anatomy of mucosal scar obstructing the
378 subglottis. Submucosal thickening with preserved cartilage seen on axial computed tomography.
379 (B) qPCR of 16S rRNA showed a significantly higher bacterial load (copy number per μL) in iLTS
380 patients (green) compared to iSGS samples (blue) ($P < 0.0001$). (C) Principal coordinate analysis
381 of proximal microbiome in iSGS, post-intubation subglottic stenosis (iLTS), and healthy controls
382 showing no significant differences in the centroids between the three groups (PerMANOVA
383 adonis2 testing $p = 0.06$). (D) Binary comparisons between healthy and iLTS samples, and
384 between healthy and iSGS samples using Bray-Curtis dissimilarities showed iSGS samples more
385 closely resembled healthy controls (Wilcoxon rank sum test with continuity correction, p -
386 value = 0.001). (E) Microbial alpha diversity (Shannon and Simpson indices), and richness (Chao1
387 index) shown for iLTS, iSGS, and healthy control samples. Individual sample values are
388 represented as dots. Group mean depicted by box center line, and standard deviation represented
389 by error bars. Microbial alpha diversity and richness were not significantly different between cases
390 and controls.

391
392 **Figure 2.** Requirement of both bacteria and host adaptive immunity to generate airway scar
393 following epithelial injury. (A) Comparison of bacterial abundance between sampling via mucosal
394 swab vs. tissue biopsy in iSGS patients. The top 20 most abundant genera detected via the two
395 methods with the genera abundance represented by boxplots; the median is represented by the
396 center line of the box, and the interquartile range is represented by the upper and lower edges of
397 the box. The vertical lines represent the whiskers (minimum and maximum, excluding outliers);
398 outliers are represented as dots. Blue boxes are samples from Hillel et al., where the iSGS
399 microbiome was sampled using swabs ($N = 5$). Red boxes are samples from the tissue samples
400 ($N = 37$). Of the top 20 most abundant genera, the only significantly different genus between the
401 two studies was *Halomonas*, which was relatively abundant in the iSGS swab samples but was

402 not found in the iSGS tissue samples. (B) Fluorescence in situ hybridization with the pan-bacterial
403 probe Eub338 shows iSGS mucosa possessed signal for bacteria in the deeper lamina propria
404 while healthy control did not. Scale bar represents 50 μ m. (C) Transmission electron microscopy
405 of separate iSGS scar specimen demonstrated numerous forms consistent with the size and
406 shape of bacteria in the cell cytoplasm. Scale bar represents 500nm. (D) An established murine
407 model of subglottic stenosis demonstrated significant thickening of the lamina propria 14 days
408 after injury in wild type (WT) mice ($p=0.0036$). No significant thickening of the lamina propria was
409 observed in either germ free mice ($p=0.56$), or severe combined immunodeficient mice (SCID)
410 ($p=0.98$). (E) WT injury was significantly greater than both GF injury ($p=0.025$) and SCID injury
411 ($p=0.036$).

412

413 **Figure 3.** Epithelial cell identification and characterization in iSGS. Uniform Manifold
414 Approximation and Projection (UMAP) of jointly analyzed single-cell transcriptomes from 25,974
415 cells from 7 iSGS mucosal scar and 3 healthy mucosa annotated by cell type. (A) Cell types/states
416 manually grouped into 4 broad tissue classes. (B) Quantification of cell types showed significantly
417 increased immune cell populations in airway scar ($p = 0.018$) and significantly reduced epithelial
418 cell numbers ($p < 0.001$) Boxes depict median and interquartile range whiskers show min to max,
419 * $P < 0.05$ by Mann-Whitney U. (C) Number of differentially expressed genes (DEG) in each cell
420 type in iSGS airway scar and paired healthy mucosa [negative binomial test, log fold change (FC)
421 cutoff of 1.5 and adjusted P value of <0.05]. (D) Detailed analysis of epithelial clusters identified
422 conserved transcriptional programs in basal (four clusters), ciliated (three clusters), secretory (one
423 cluster), and a proliferating cell subset (one cluster) in both healthy and scar (E). (F) Quantification
424 of cell types in iSGS airway scar versus matched healthy mucosa. Boxes depict median and
425 interquartile range whiskers show min to max, * $P < 0.05$ by Mann-Whitney U. (G) Differentially
426 expressed gene (DEG) analysis for Hallmark genesets, Gene Ontology biological processes
427 genesets in proliferating epithelial cells in iSGS airway scar compared to healthy mucosa (logFC,

428 >0.5; FDR, <0.1). GSE: Geneset enrichment. Blue represents genesets upregulated in scar
429 epithelium, yellow represents genesets downregulated in scar epithelium compared to healthy
430 mucosa. mTORC1: mechanistic target of rapamycin complex 1, OxPhos: oxidative
431 phosphorylation, EMT: epithelial-mesenchymal transition.

432

433 **Figure 4.** Immune cell identification and functional characterization in iSGS Proximal Airway Scar.

434 (A) UMAP of jointly analyzed single-cell transcriptomes annotated by cell type displaying adaptive
435 immune cells (T cells and NK cells). (B) Analysis of immune clusters identified conserved
436 transcriptional programs in T cells (four clusters) and NK cells (two clusters), with differential
437 abundance in healthy mucosa and airway scar. (C) Quantification of immune cell types in iSGS
438 airway scar versus matched healthy mucosa. Boxes depict median and interquartile range
439 whiskers show min to max, *P < 0.05 by Mann-Whitney U. (D). Single cell suspensions from 5
440 unique iSGS patients cultured in the presence of matched iSGS airway microbiome, the
441 microbiome from an unrelated healthy subject, or left untreated. 24 hours after stimulation,
442 expression levels of activation marker CD154 were quantified on CD4+ and CD8+ T cells. (E)
443 Both the matched iSGS microbiome, as well as the microbiome from an unrelated healthy control
444 significantly up-regulated CD154 when compared to untreated experimental controls (CD4+
445 matched iSGS microbiome vs untreated: p=0.007; CD4+ unrelated healthy microbiome vs
446 untreated: p=0.04), (CD8+ matched iSGS microbiome vs untreated: p=0.005; CD8+ unrelated
447 healthy microbiome vs untreated: p=0.03). No significant difference observed between cells
448 treated with a matched iSGS microbiome or cells treated with an unrelated healthy microbiome.

449 **REFERENCES**

- 450 1. F. Maldonado *et al.*, Idiopathic subglottic stenosis: an evolving therapeutic
451 algorithm. *Laryngoscope* **124**, 498-503 (2014).
- 452 2. A. Gelbard *et al.*, Causes and consequences of adult laryngotracheal stenosis.
453 *Laryngoscope* **125**, 1137-1143 (2015).
- 454 3. A. Gelbard *et al.*, Disease homogeneity and treatment heterogeneity in idiopathic
455 subglottic stenosis. *Laryngoscope* **126**, 1390-1396 (2016).
- 456 4. A. Gelbard *et al.*, Comparative Treatment Outcomes for Patients With Idiopathic
457 Subglottic Stenosis. *JAMA Otolaryngol Head Neck Surg*, 1-10 (2019).
- 458 5. S. H. Gnagi, B. E. Howard, C. Anderson, D. G. Lott, Idiopathic Subglottic and
459 Tracheal Stenosis: A Survey of the Patient Experience. *Ann Otol Rhinol Laryngol*
460 **124**, 734-739 (2015).
- 461 6. J. J. Daniero, D. C. Ekbom, A. Gelbard, L. M. Akst, A. T. Hillel, Inaugural
462 Symposium on Advanced Surgical Techniques in Adult Airway Reconstruction:
463 Proceedings of the North American Airway Collaborative (NoAAC). *JAMA*
464 *Otolaryngol Head Neck Surg* **143**, 609-613 (2017).
- 465 7. E. J. Mark, F. Meng, R. L. Kradin, D. J. Mathisen, O. Matsubara, Idiopathic tracheal
466 stenosis: a clinicopathologic study of 63 cases and comparison of the pathology
467 with chondromalacia. *The American journal of surgical pathology* **32**, 1138-1143
468 (2008).
- 469 8. T. A. Wynn, T. R. Ramalingam, Mechanisms of fibrosis: therapeutic translation for
470 fibrotic disease. *Nat Med* **18**, 1028-1040 (2012).
- 471 9. P. C. Blainey, C. E. Milla, D. N. Cornfield, S. R. Quake, Quantitative analysis of the
472 human airway microbial ecology reveals a pervasive signature for cystic fibrosis.
473 *Sci Transl Med* **4**, 153ra130 (2012).
- 474 10. D. N. O'Dwyer *et al.*, Lung Microbiota Contribute to Pulmonary Inflammation and
475 Disease Progression in Pulmonary Fibrosis. *Am J Respir Crit Care Med* **199**, 1127-
476 1138 (2019).
- 477 11. R. A. Clark, Resident memory T cells in human health and disease. *Sci Transl Med*
478 **7**, 269rv261 (2015).
- 479 12. A. T. Hillel *et al.*, Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis.
480 *mSphere* **4**, (2019).
- 481 13. G. D. Kitsios *et al.*, Microbiome in lung explants of idiopathic pulmonary fibrosis: a
482 case-control study in patients with end-stage fibrosis. *Thorax* **73**, 481-484 (2018).

- 483 14. A. T. Hillel *et al.*, An in situ, in vivo murine model for the study of laryngotracheal
484 stenosis. *JAMA Otolaryngol Head Neck Surg* **140**, 961-966 (2014).
- 485 15. A. O. Vladutiu, The severe combined immunodeficient (SCID) mouse as a model
486 for the study of autoimmune diseases. *Clin Exp Immunol* **93**, 1-8 (1993).
- 487 16. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell
488 RNA-seq data using regularized negative binomial regression. *Genome Biol* **20**,
489 296 (2019).
- 490 17. T. Stuart *et al.*, Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-
491 1902 e1821 (2019).
- 492 18. I. Korsunsky *et al.*, Fast, sensitive and accurate integration of single-cell data with
493 Harmony. *Nat Methods* **16**, 1289-1296 (2019).
- 494 19. O. Franzen, L. M. Gan, J. L. M. Bjorkegren, PanglaoDB: a web server for
495 exploration of mouse and human single-cell RNA sequencing data. *Database*
496 (*Oxford*) **2019**, (2019).
- 497 20. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: a Bioconductor package for
498 differential expression analysis of digital gene expression data. *Bioinformatics* **26**,
499 139-140 (2010).
- 500 21. J. E. McDonough *et al.*, Small-airway obstruction and emphysema in chronic
501 obstructive pulmonary disease. *N Engl J Med* **365**, 1567-1575 (2011).
- 502 22. S. R. Rutgers *et al.*, Ongoing airway inflammation in patients with COPD who do
503 not currently smoke. *Thorax* **55**, 12-18 (2000).
- 504 23. V. V. Polosukhin *et al.*, Secretory IgA Deficiency in Individual Small Airways Is
505 Associated with Persistent Inflammation and Remodeling. *Am J Respir Crit Care*
506 *Med* **195**, 1010-1021 (2017).
- 507 24. B. W. Richmond *et al.*, Monocyte-derived dendritic cells link localized secretory IgA
508 deficiency to adaptive immune activation in COPD. *Mucosal Immunol* **14**, 431-442
509 (2021).
- 510 25. H. Fehrenbach, C. Wagner, M. Wegmann, Airway remodeling in asthma: what
511 really matters. *Cell Tissue Res* **367**, 551-569 (2017).
- 512 26. R. P. Schleimer, S. Berdnikovs, Etiology of epithelial barrier dysfunction in patients
513 with type 2 inflammatory diseases. *J Allergy Clin Immunol* **139**, 1752-1761 (2017).
- 514 27. M. A. Seibold *et al.*, A common MUC5B promoter polymorphism and pulmonary
515 fibrosis. *N Engl J Med* **364**, 1503-1512 (2011).

- 516 28. A. Pardo, M. Selman, Idiopathic pulmonary fibrosis: new insights in its
517 pathogenesis. *Int J Biochem Cell Biol* **34**, 1534-1538 (2002).
- 518 29. B. L. Hogan *et al.*, Repair and regeneration of the respiratory system: complexity,
519 plasticity, and mechanisms of lung stem cell function. *Cell Stem Cell* **15**, 123-138
520 (2014).
- 521 30. J. A. Voynow, B. M. Fischer, B. C. Roberts, A. D. Proia, Basal-like cells constitute
522 the proliferating cell population in cystic fibrosis airways. *Am J Respir Crit Care*
523 *Med* **172**, 1013-1018 (2005).
- 524 31. N. F. Smirnova *et al.*, Detection and quantification of epithelial progenitor cell
525 populations in human healthy and IPF lungs. *Respir Res* **17**, 83 (2016).
- 526 32. A. E. Vaughan *et al.*, Lineage-negative progenitors mobilize to regenerate lung
527 epithelium after major injury. *Nature* **517**, 621-625 (2015).
- 528 33. P. A. Kumar *et al.*, Distal airway stem cells yield alveoli in vitro and during lung
529 regeneration following H1N1 influenza infection. *Cell* **147**, 525-538 (2011).
- 530 34. E. G. O'Koren, B. L. Hogan, M. D. Gunn, Loss of basal cells precedes bronchiolitis
531 obliterans-like pathological changes in a murine model of chlorine gas inhalation.
532 *Am J Respir Cell Mol Biol* **49**, 788-797 (2013).
- 533 35. J. H. Trevino-Villarreal *et al.*, Down-Regulation of a Profibrotic Transforming
534 Growth Factor-beta1/Cellular Communication Network Factor 2/Matrix
535 Metalloprotease 9 Axis by Triamcinolone Improves Idiopathic Subglottic Stenosis.
536 *Am J Pathol* **191**, 1412-1430 (2021).
- 537 36. M. Laplante, D. M. Sabatini, mTOR signaling in growth control and disease. *Cell*
538 **149**, 274-293 (2012).
- 539 37. P. Hofman, V. Vouret-Craviari, Microbes-induced EMT at the crossroad of
540 inflammation and cancer. *Gut Microbes* **3**, 176-185 (2012).
- 541 38. A. Aldhahrani *et al.*, The Potential Role of Bile Acids in Acquired Laryngotracheal
542 Stenosis. *Laryngoscope* **128**, 2029-2033 (2018).
- 543 39. A. D. Friedman, O. Dan, J. A. Drazba, R. R. Lorenz, M. Strome, Quantitative
544 analysis of OX62-positive dendritic cell distribution in the rat laryngeal complex.
545 *Ann Otol Rhinol Laryngol* **116**, 449-456 (2007).
- 546 40. P. Jecker *et al.*, Acute laryngitis in the rat induced by *Moraxella catarrhalis* and
547 *Bordetella pertussis*: number of neutrophils, dendritic cells, and T and B
548 lymphocytes accumulating during infection in the laryngeal mucosa strongly differs
549 in adjacent locations. *Pediatr Res* **46**, 760-766 (1999).

- 550 41. S. Y. Lee *et al.*, Mucociliary transport pathway on laryngotracheal tract and stented
551 glottis in guinea pigs. *Ann Otol Rhinol Laryngol* **109**, 210-215 (2000).
- 552 42. V. E. Drake *et al.*, Familial Aggregation in Idiopathic Subglottic Stenosis.
553 *Otolaryngol Head Neck Surg* **163**, 1011-1017 (2020).
- 554 43. M. F. Moffatt *et al.*, A large-scale, consortium-based genomewide association
555 study of asthma. *N Engl J Med* **363**, 1211-1221 (2010).
- 556 44. M. H. Cho *et al.*, Risk loci for chronic obstructive pulmonary disease: a genome-
557 wide association study and meta-analysis. *Lancet Respir Med* **2**, 214-225 (2014).
- 558 45. J. A. Kropski, T. S. Blackwell, J. E. Loyd, The genetic basis of idiopathic pulmonary
559 fibrosis. *Eur Respir J* **45**, 1717-1727 (2015).
- 560 46. B. Driscoll, S. Buckley, K. C. Bui, K. D. Anderson, D. Warburton, Telomerase in
561 alveolar epithelial development and repair. *Am J Physiol Lung Cell Mol Physiol*
562 **279**, L1191-1198 (2000).
- 563 47. M. E. Schmidt, S. M. Varga, The CD8 T Cell Response to Respiratory Virus
564 Infections. *Front Immunol* **9**, 678 (2018).
- 565 48. A. Gelbard *et al.*, Molecular analysis of idiopathic subglottic stenosis for
566 Mycobacterium species. *Laryngoscope* **127**, 179-185 (2017).
- 567 49. K. Bachmaier *et al.*, Chlamydia infections and heart disease linked through
568 antigenic mimicry. *Science* **283**, 1335-1339 (1999).
569

Figure 1.






Figure 2.


A.




B.



C.



D.



E.




Figure 3.





Figure 4.



1 **Idiopathic subglottic stenosis arises at the interface of host and pathogen.**

2

3 Alexander Gelbard¹, Meghan H. Shilts², Britton Strickland³, Kevin Motz⁵, Hsiu-Wen

4 Tsai⁵, Helen Boone², Wonder P. Drake³, Celestine Wanjalla³, Paula Marincola Smith⁶,

5 Hunter Brown², Marisol Ramirez⁸, James B. Atkinson⁴, Jason Powell^{7, 8}, A John

6 Simpson^{7, 8}, Seesandra V. Rajagopala², Simon Mallat^{2, 3}, Quanhu Sheng⁹, Alexander T.

7 Hillel⁵, Suman R. Das^{2, 3}

8

9 **Supplementary Material**

10

11

12 Contents:

13

1. Methods (**pages 2-12**)

14

a. Case and Control definitions

15

b. Tissue Biopsy

16

c. DNA extraction, quantitative PCR and 16S rRNA sequencing

17

d. Fluorescence in situ Hybridization (FISH)

18

e. Transmission Electron Microscopy (TEM)

19

f. Single Cell RNA sequencing (scRNAseq)

20

g. Differential Gene Expression (DEG)

21

h. Gene Set Enrichment analysis (GESA)

22

i. In Vitro Cell Culture

23

j. Flow Cytometry

24

k. Statistical Analysis

25

2. Supplementary Tables and Figures (**pages 13-22**)

26

a. Table 1: Samples utilized for 16s sequencing and bacterial analysis

27

b. Table 2: Samples utilized for scRNAseq sequencing and analysis

28

c. Table 3: Distribution of scRNAseq samples by site

29

d. Figure 1: Bacterial Genera and Family from iSGS, iLTS, and Healthy Control

30

e. Figure 2: Relationship between iSGS severity and bacterial community structure

31

f. Figure 3: UMAP of individual scRNAseq samples

32

g. Figure 4: UMAP of individual scRNAseq Batches

33

h. Figure 5: Expression of canonical cell-type markers among clusters

34

i. Figure 6: Global Cell Clusters

35

j. Figure 7. Confirmatory Flow Cytometry

36

k. Figure 8. Differential Gene Expression in each cell type

37

38

3. Supplementary Bibliography (**pages 23-24**)

39

40

41

42

43 **EXTENSIVE METHODS**

44 **Case definitions:**

45 We diagnosed Idiopathic Subglottic Stenosis (iSGS) according to standard clinical
46 criteria.^{1,2} In brief, patients had no history of endotracheal intubation or tracheotomy within
47 2 years of presentation. They had no history of significant laryngotracheal injury, thyroid
48 or major anterior neck surgery, or neck irradiation. They had no caustic or thermal injuries
49 to the laryngotracheal complex. They had no clinical history of vasculitis and negative titers
50 antinuclear cytoplasmic antibody (ANCA). Anatomically, the airway stenosis involved the
51 subglottis. (Supplementary Table S1).

52

53 **Control definitions:**

54 Post intubation Subglottic Stenosis (iLTS): Patients who developed subglottic or tracheal
55 stenosis within 2 years of intubation or following tracheostomy.^{1,2}

56

57 Healthy Subglottis: Healthy control subjects underwent elective direct laryngoscopy under
58 general anesthesia for a range of upper aerodigestive symptoms but normal subglottic
59 examination and had subglottic mucosal biopsies collected using a sheathed cytology
60 brush (BC-202D-5010; Olympus)

61

62 **Study Procedures:**

63 *Microbiome Assessment.* We performed tissue sampling of the affected airway in the
64 operating room in patients undergoing surgical treatment for their airway stenosis.
65 Mucosal brush biopsies from healthy controls were also obtained under direct endoscopic

66 vision in the operating room during elective laryngoscopy under general anesthesia. In
67 patients with mucosal scar undergoing tissue biopsy, after surgical exposure of the
68 subglottis during direct laryngoscopy, the airway mucosa was washed with 10cc of sterile
69 saline. After rinsing the mucosa sterile upbiting cup forceps were used for mucosal biopsy.
70 Without any break in sterility, a researcher received the mucosal explant in the operating
71 room immediately after transfer from the surgical field. Tissue samples were placed in
72 sterile RNAlater solution and stored at -80°C. Similarly, subglottic mucosal brush biopsies
73 from healthy controls were directly placed in sterile RNAlater solution and stored at -80°C.

74

75 ***DNA extraction, quantitative PCR and 16S rRNA gene sequencing.***

76 *DNA Extraction:* DNA was extracted with the DNeasy PowerSoil Kit (Qiagen). Mechanical
77 lysis of bacterial cell walls was performed by shaking the samples on a TissueLyser II
78 (Qiagen) for 20 minutes total. Due to the expected low bacterial biomass of tissue
79 samples, a total of 10 negative controls were processed concurrently with the samples (8
80 of which were extraction negative controls and 2 of which were PCR negative controls).

81

82 *Determination of bacterial load by qPCR:* DNA input was standardized by equal
83 volumes due to standardized sample size and multiplexed DNA extraction methods. Equal
84 volumes of DNA were added to triplicate reactions containing universal 16S rRNA primers
85 (UniF340 actcctacgggaggcagcagt, UniR514 attaccgcggtgctggc)³, BioRad iQ Supermix,
86 and Invitrogen SYBR DNA stain following the manufacturer's protocol. Each qPCR plate
87 included a corresponding extraction negative and a no-template negative control. A serial
88 dilution of standards containing known bacterial copy numbers specific to the primer pair
89 were used as a standard curve as previously described. PCR reactions were run using a
90 BioRad CFX96 Real-Time PCR Detection System with a 15s 95°C melting and 1 minute

91 54°C annealing step for 40 cycles. CT values were plotted against the standard curve to
92 determine copy number. Figure generation and statistical values were generated using
93 Prism version 8.

94

95 **16S rRNA Library Construction:** Dual-indexed universal primers appended with
96 Illumina-compatible adapters were used to amplify the hypervariable V4 region of the
97 bacterial 16S rRNA gene.⁴ The PCR mix for each library contained 12.5 µl of MyTaq Mix
98 (Bioline), 0.75 µl DMSO, 1 µl of forward primer, 1 µl of reverse primer, 7 µl of extracted
99 DNA, and PCR Certified water (Teknova) was added to achieve a final volume of 25.25
100 µl. DNA was denatured at 95°C for 2 min, and then 30 cycles of 95°C for 20 seconds,
101 55°C for 15 seconds, and 72°C were performed. Samples were then incubated at 72°C
102 for 10 min, and samples were held at 4°C until removal from the thermocycler. Each
103 sample was run on a 1% agarose gel to verify reaction success. Libraries were cleaned
104 and normalized with the Invitrogen SequalPrep Kit. After normalization to 1-2 ng/µl, 10 µl
105 of each sample were combined to create the sequencing pool. The pool was cleaned with
106 1X AMPure XP beads (Beckman Coulter, Brea, California). Libraries were sequenced on
107 an Illumina MiSeq with 2x250 bp reads. A mock community control (ZYMObiomics) and
108 extraction and PCR negative controls were run concurrently along with the samples to
109 assess data quality and levels of background contamination.

110

111 *16S Sequence Processing.* We processed the 16S rRNA sequences with the dada2
112 pipeline by following the standard operating procedure (available at:
113 <https://benjjneb.github.io/dada2/tutorial.html>, as of 7.16.2019).⁵ Sequences were grouped
114 into amplicon sequence variants (ASVs)⁶, and taxonomy was assigned using the SILVA
115 reference database.⁷ Sequences were subsequently processed through the R package

116 decontam⁸ to remove any suspected contaminants that were found in the negative control
117 samples. Potential contaminants were detected with the decontam “prevalence” method,
118 in which presence/absence of sequences in negative controls is compared to that of real
119 samples. The R package phyloseq⁹ was used to facilitate downstream data processing.
120 Figures were generated with the R package ggplot2.¹⁰

121

122 *Comparison of tissue-based and swab-based sampling of microbial species in iSGS.* In
123 Hillel et al., superficial swabs of airway mucus were used to characterize the microbiome
124 ¹¹, while in our study we sampled the tissue directly. We downloaded the FASTQ files
125 available from the first study to compare the superficial microbiome with the deeper tissue
126 microbiome from in our study as described above.

127

128 ***Fluorescence in situ Hybridization.*** Fluorescence in situ Hybridization (FISH) was
129 performed as previously described¹². In brief, custom oligonucleotides were generated by
130 the Vanderbilt University Molecular Cell Biology Resource Core in partnership with
131 Sigma/Genosys (Woodlands, TX). The pan-bacterial probe (Eub338) and negative control
132 probe (Non-Eub) sequences are listed in Table 1, below. Three diseased tracheal
133 specimens and one healthy control tracheal specimen in FFPE were used for this analysis.
134 Human specimens were stained with custom oligonucleotides as previously described.
135 FFPE blocks were cut into 5-micron sections on charged slides and placed in a
136 hybridization oven at 50° C for 10 minutes to melt paraffin and then de-paraffinized in
137 HistoClear[®] (National Diagnostics) and re-hydrated by ethanol gradient before being
138 placed in 20 mM Tris buffer. Bacterial probes were diluted to 2 μM in pre-warmed
139 hybridization buffer (20 mM Tris-HCl [pH 8.0] + 0.9 M NaCl + 0.01% sodium dodecyl
140 sulfate). Approximately 150 μL probe solution was then placed on each slide until sample

141 was completely covered and slides were incubated for 1.5 hours at 46° C in humidity
142 chamber. Slides were then washed in FISH wash buffer (225 mM NaCl + 20 mM Tris + 5
143 mM EDTA) for 5 minutes, three times, before being counterstained with DAPI (1:1,000
144 diluted in PBS) for 5 minutes. Slides were then washed again in FISH wash buffer for five
145 minutes, twice. Slides were then cover slipped with ProLong Gold Antifade (Invitrogen)
146 and allowed to cure in the dark for 24 hours prior to sealing.

147

Fluorescence in situ Hybridization (FISH) Probes	
Eub338	5' – Cy3 – GCTGCCTCCCGTAGGAGT – 3'
Non-Eub (Negative Control)	5' – Cy3 – CGACGGAGGGGCATCCTCA – 3'
Table 1: Fluorescence in situ Hybridization (FISH) probes utilized.	

148

149

150

151 **Transmission Electron Microscopy (TEM).** Specimens were processed for TEM and
152 imaged in the Vanderbilt Cell Imaging Shared Resource-Research Electron Microscopy
153 facility as previously described. In brief, samples were fixed in 2.5% gluteraldehyde in
154 0.1M cacodylate buffer, pH7.4 at room temperature (RT) 1 hour then transferred to 4°C,
155 overnight. The samples were washed in 0.1M cacodylate buffer, then incubated 1 hour
156 in 1% osmium tetroxide at RT then washed with 0.1M cacodylate buffer. Subsequently,
157 the samples were dehydrated through a graded ethanol series and then 3 exchanges of
158 100% ethanol, followed by 2 exchanges of pure propylene oxide (PO). Samples were
159 then infiltrated with 25% Epon 812 resin and 75% PO for 30 minutes at RT. Next, they
160 were infiltrated with Epon 812 resin and PO [1:1] for 1 hour at RT then overnight at RT.

161 The samples are subsequently infiltrated with resin for 48 hours then allowed to
162 polymerize at 60°C for 48 hours. 70-80nm ultra-thin sections were cut and collected on
163 300-mesh copper grids and post-stained with 2% uranyl acetate and then with Reynold's
164 lead citrate. Samples were subsequently imaged on the Philips/FEI Tecnai T12 electron
165 microscope at various magnifications.

166

167 ***Single Cell RNA sequencing***

168 ***Tissue processing.*** Tissue sampling of the affected airway in the operating room in
169 patients undergoing surgical treatment for their airway stenosis was preformed similar to
170 tissue acquisition for 16S sequencing. After surgical exposure of the subglottis during
171 direct laryngoscopy, the airway mucosa was washed with 10cc of sterile saline. After
172 saline rinse, sterile upbiting cup forceps were used for mucosal biopsy. Without any break
173 in sterility, a researcher received the mucosal explant in the operating room immediately
174 after transfer from the surgical field. Tissue samples were placed in sterile room
175 temperature saline and immediately transferred to the lab for tissue digestion. Biopsies
176 were digested as previously described. In brief, samples were placed in an enzymatic
177 cocktail [collagenase I/dispase II (1 µg/ml) tissue for 60 minutes followed by mechanical
178 disruption. Tissue lysates were serially filtered 100- and 40-µm sterile filters (Fischer) and
179 used as input for generation of scRNA-seq libraries.

180

181 ***scRNA-seq library preparation and next-generation sequencing.*** scRNA-seq libraries were
182 generated using the 10x Chromium platform 3' v2 or 5' library preparation kits (10x
183 Genomics) following the manufacturer's recommendations and targeting 5000 to 10,000
184 cells per sample. Next-generation sequencing was performed on an Illumina NovaSeq
185 6000.

186

187 *Reference Mapping, Cluster annotation, Differential Gene Expression (DEG), Gene Set*
188 *Enrichment analysis (GESA):* 10x Genomics Cell Ranger¹³ 5.0.0 was used to build
189 reference genome index, map reads to reference genome (GRCh38-2020-A) and quantify
190 genes. The cells labeled with sample-specific hashtags were demultiplexed by in-house
191 scripts. scRNABatchQC¹⁴ was used for quality control. Cells were removed if they had
192 unique features counts of less than 200 or larger than 8000, had fewer than 500 read
193 counts and/or had greater than 40% mitochondrial read counts. Seurat¹⁵ was used for
194 clustering analysis with SCTransform based normalization. Cell type of each cluster was
195 initially classified based on cell activity database¹⁶ and then manually refined based on
196 cell type specific marker gene expression. edgeR¹⁷ was used to detect differential
197 expression across conditions. Gene set enrichment analysis was performed using GSEA
198 package¹⁸. Based on significantly differential expressed genes, Gene Ontology (GO) and
199 pathway analysis was performed using WebGestaltR package¹⁹.

200

201

202

203 ***Data and code accessibility***

204 Raw and processed 16S sequencing data can be found under Bioproject. Raw and
205 processed 10x Genomics data can be found on GEO using accession number
206 GSE191128.

207

208

209 ***In Vitro Cell Culture***

210 Tissue biopsies acquired during operative endoscopy of 5 unique iSGS patients were used
211 to create fresh single cell suspensions as described above. Suspensions were rested for 6
212 hours in RPMI Complete Subglottic Media [RPMI + L-GLUT, 10% FCS + NEAA + IL-15

213 (25ng/ml) + 17B2 (1X10⁻¹²M Estrogen)]. During the operative endoscopy 5mL of saliva
214 was also collected from each matched iSGS patient and unrelated healthy control. These
215 samples were used to generate an oropharyngeal microbiome based on published
216 methods²⁰. In brief, saliva samples were centrifuged at 2,000g for 5 mins to spin down
217 large debris and eukaryotic cells. Next 1mL supernatant is removed from the sample and
218 added to 1mL PBS (total of 2 mL) and stored anaerobically at 37degree C until use. After
219 the period of rest, cells were cultured in the presence of a matched iSGS airway
220 microbiome, the microbiome from an unrelated healthy subject, or left untreated. 24 hours
221 after initiation stimulation, cells were washed twice in PBS and stained, and analyzed via
222 flow cytometry.

223

224

225 **Flow Cytometry:** Single cell suspensions were prepared and adjusted to a concentration
226 adjusted to 10⁶/ml. To block nonspecific staining due to Fc receptor (FcR) binding, cells
227 were preincubated with 5ul FcR Blocking Solution (Human TruStain FcX™, Biolegend inc,
228 San Diego Ca. Cat. #422301) in 50ul PBS/2%FCS (Phosphate Buffered Solution, Fetal
229 Calf Serum) per 1X10⁶ cells for 10min at 4°C. The cells were not washed after FC
230 blocking prior to the first staining step. Cells were then incubated 30 minutes at 4°C in a
231 staining buffer (approx. 10⁶ cells in 100µl of staining buffer). The staining buffer
232 contained a pre-titrated, optimal concentration (\leq 5µg) of fluorescent monoclonal
233 antibodies specific for a receptor or with an immunoglobulin (Ig) isotype-matched control
234 respectively (see below for details). After the incubation, cells were washed 2x with 200ul
235 of staining buffer and pelleted by centrifugation (250 X g for 5 min). Finally, cells were
236 resuspended in PBS/2%FCS for flow cytometric analysis. All flow cytometry experiments
237 were acquired with an LSR-II flow cytometer (BD Biosciences). Analysis was performed
238 using FlowJo, LLC software (FlowJo, LLC, Ashland, OR).

239

240 Cells were gated by FSC/SSC, doublets were gated out, followed by exclusion of dead
241 cells, and then cells were analyzed for characteristic surface protein expression. T cells
242 were defined as CD45+ & CD326^{neg}, CD3+, and either CD4+ or CD8+. In co-culture
243 experiments CD154 expression was evaluated on CD4+ and CD8+ T cells.

244

245 Flow Cytometry Reagents Utilized

Characteristic	Analyte	Detector	Reporter	Manufacture	Clone	Cat#
Pan-Immune	CD45	Anti- CD45	AF700	BioLegend	HI30	304024
Pan Epithelial	CD326 (EPCAM)	Anti-CD326	PE/Cy7	BioLegend	9C4	324222
T Cells	CD3	Anti-CD3	BV605	BioLegend	OKT3	317322
CD4+ T Cells	CD4	Anti- CD4	PerCP	BioLegend	RPA-T4	300530
CD8+ T Cells	CD8	Anti-CD8a	FITC	BioLegend	RPA-T8	301050
T-Cell Activation	CD154	Anti-CD154	APC/Cy7	BioLegend	24-31	310822
Cell viability	DNA (compromised cells)	LIVE/DEAD™	Fixable Aqua	Thermofisher	N/A	L34957

246

247 **Statistical Analyses**

248 ***Microbiome / 16S sequencing:*** Our primary interest was comparison of the tissue
249 microbiome of iSGS and post-intubation (iLTS) patients versus healthy controls. Additional
250 secondary analyses tested the relationship of 1. disease severity (quantified as the
251 number of procedures/year) and with microbial species in iSGS patients. To contextualize
252 our findings with the published evidence in the field, we also compared our iSGS
253 sequencing data with available published sequencing data for iSGS patients from airway
254 mucosal swabs (from the Hillel et al. study)¹¹.

255 We set a read cutoff of 500 sequences per sample (2 standard deviations above the
256 maximum number of reads retained in any of the negative controls). We calculated
257 descriptive statistics and performed comparisons with non-parametric statistical tests
258 using the R platform.²¹ Taxonomic descriptions, richness and alpha- diversity metrics were
259 calculated with the R package *vegan*²² at the amplicon sequence variants (ASV) level. To

260 control for differences in sequencing depths, counts were randomly rarefied to the lowest
261 library size of all samples and then each microbial ecology index was computed. For each
262 index, this rarefaction and computation process was repeated multiple times (n=400), and
263 the results were averaged.

264 Beta diversity was assessed using the Bray-Curtis dissimilarity index with
265 PerMANOVA testing implemented in Adonis2²³ to identify differences in community
266 structure between iSGS cases, iLTS controls, and healthy samples at the ASV level.
267 Principle coordinates analysis (PCoA) was performed in *vegan* in order to ordinate the
268 dissimilarity data and plot it in two dimensional space. PCoA vectors and centroids were
269 extracted with the *betadisper* function. Percent of variance explained by each PCoA axis
270 was calculated by dividing its eigenvalue over the sum of all PCoA eigenvalues and
271 multiplying by 100.

272 Secondary analyses testing associations between disease severity
273 (procedures/year) with bacterial ASVs in iSGS were assessed using the R package
274 DESeq2 (with p- or q-value as appropriate < 0.05).²⁴ We eliminated ASVs that were
275 detected on average <10 times, ASVs with a minimum quantile mean fraction <0.25, and
276 ASVs with a minimum quantile incidence fraction <0.25. The absolute counts from the
277 removed ASVs were aggregated into a category “other”, which was taken into account
278 when computing simple proportions during data normalization but were otherwise
279 discarded. This was done to reduce the penalty associated with multiple comparisons and
280 to remove likely non-informative data.

281 The DESeq2 test uses shrinkage estimation for dispersions and fold changes to
282 improve the stability and interpretability of estimates. This method models raw absolute
283 counts of each taxon with a negative binomial distribution and uses the estimated depth
284 of sequencing of each sample to scale the (unknown) relative abundance that is the

285 parameter of the negative binomial distribution. Compared to using either simple
286 proportion-based normalization or rarefaction to control for differences in sequencing
287 depth, the DESeq2 test provides improved sensitivity and specificity.²⁵ Default outlier
288 detection and replacement was used as described.²⁴ Reported q-values are the result of
289 a Wald test with the Benjamini-Hochberg correction²⁶ applied to adjust for multiple
290 comparisons.

291

292 *Additional Statistical Methods:* Additional analyses were conducted with Prism (GraphPad
293 Software). Nonparametric data were analyzed by Mann-Whitney U test for two variables
294 and by Kruskal-Wallis test for greater than two variables, using Dunn's post hoc analysis
295 test. Categorical data were assessed by Fisher's exact test. Correlations were assessed
296 by linear regression. A P value less than 0.05 was considered statistically significant.

297

298 **ROLE OF THE FUNDING SOURCE:** The study sponsor had no role in the analysis or
299 interpretation of the data and was not involved in the writing of the manuscript or
300 decision to submit the paper for publication. The corresponding author had full access to
301 the data and final responsibility for the decision to submit for publication.

302

SUPPLEMENTAL RESULTS (Tables and Figures)

Table S1. Clinical Data for iSGS Cases and Controls Utilized in 16S Sequencing.

Table S1. Patient Characteristics	iSGS (n=50)	iLTS (n=27)	Significance (p)
<i>Demographics</i>			
Age (Mean years, 95% CI)	47 (43 - 51)	48 (41 - 54)	ns ¹
Sex (% Female)	100	66	0.001 ²
Race (% Caucasian)	100	93	0.017 ²
Ethnicity (% Non-Hispanic or Latino)	100	100	ns ²
<i>Disease Morphology</i>			
% Stenosis (Mean %, 95% CI)	54 (48 - 60)	73 (57 - 89)	0.018 ¹
Stenosis Length (Mean mm, 95% CI)	12 (10 - 14)	19 (15 - 22)	<0.001 ¹
Distance below glottis (Mean mm, 95% CI)	13 (12 - 15)	21 (16 - 26)	<0.001 ¹
<i>Treatment History</i>			
Total Number of Surgical Procedures	7.2 (5 - 9)	7.7 (5 - 10)	ns ¹
<i>Health / Endocrine Status</i>			
Charlson Comorbidity Index (Mean, 95% CI)	1.67 (0 - 0)	2.71 (0 - 0)	0.012 ¹
GERD (% positive)	46	48	ns ²
DMII (% positive)	12	62	<0.001 ²
COPD (% positive)	0	30	<0.001 ²
<i>Follow-up Duration</i>			
Years of Follow up (Mean months, 95% CI)	71 (54 - 88)	30 (14 - 46)	0.002 ¹

Demographic and disease information for Idiopathic subglottic stenosis (iSGS), and post-intubation subglottic stenosis controls (iLTS). Mean (95% CI) for continuous variables. Covariates distinguishing diseases were sex (iSGS patients were all female) and ethnicity (iSGS patients were exclusively Caucasian). iLTS patients also had a longer length stenosis, with a greater degree of luminal obstruction, arising farther from the glottis. A greater percentage of iLTS patients had comorbid diabetes mellitus type II (DMII), and Chronic obstructive pulmonary disease (COPD). The median duration of patient follow-up was longer in iSGS patients. Tests used: 1: Kruskal-Wallis test; 2: Pearson test.

354 **Supplemental Table S2: Demographics of Specimens Utilized for scRNAseq**
355 **experiments.**
356
357

Table S2. Patient Characteristics for Samples Utilized for scRNAseq

Patient ID	Sex	Diagnosis	Race	
1	Female	iSGS	Caucasian	<i>matched w/ 10</i>
2	Female	iSGS	Caucasian	<i>matched w/ 9</i>
3	Female	iSGS	Caucasian	<i>matched w/ 8</i>
4	Female	iSGS	Caucasian	
5	Female	iSGS	Caucasian	
6	Female	iSGS	Caucasian	
7	Female	iSGS	Caucasian	
8	Female	iSGS	Caucasian	
9	Female	iSGS	Caucasian	
10	Female	iSGS	Caucasian	

358
359
360
361
362
363


Supplemental Table S3: Sequencing Location of Samples utilized for scRNAseq experiments.

Table S3. Sequencing Location of Samples

Patient ID	Tissue	Sequencing Institution
1	Healthy	Vanderbilt University
2	Healthy	Johns Hopkins
3	Healthy	Johns Hopkins
4	Scar	Vanderbilt University
5	Scar	Vanderbilt University
6	Scar	Vanderbilt University
7	Scar	Johns Hopkins
8	Scar	Johns Hopkins
9	Scar	Johns Hopkins
10	Scar	Vanderbilt University

Samples 1,4,5,6,10 were completed at Vanderbilt University and samples 2,3,7,8,9 were completed at Johns Hopkins. Both sites sequenced scar and matched healthy mucosal control

372 **Figure S1. Relative bacterial abundance in iSGS cases and controls.**




373
 374 Relative abundance of the top 20 most abundant A) families and B) genera in a stacked
 375 bar chart. Each sample represented as a unique column. Samples grouped into iSGS
 376 cases and post-intubation subglottic stenosis (iLTS) and healthy mucosal controls.
 377

378
 379
 380
 381
 382
 383
 384
 385
 386
 387

388

389 **Figure S2. Relationship between iSGS disease severity and bacterial load and**
390 **microbial diversity.**

391



392

393 There was not a significant association between iSGS disease severity (calculated as the
394 number of procedures/year) and overall bacterial load (as quantified by 16S rRNA copy
395 number, p-value = 0.953, Figure S2A). Nor was there an association between disease
396 severity and alpha diversity (p-value = 0.453, Figure S2B) or richness (p-value = 0.6078,
397 data not shown).

398

399

400

401

402

403

404

405

406

407

408

409

410


411

412

413

414 **Figure S3. UMAP of individual samples.**

415



416


417

418 UMAP for each individual sample utilized (n=10: scar =7, matched healthy mucosa=3).
419 There were not significant differences observe across biologic replicates.

420

421

422 **Figure S4. UMAP of sequencing batches.**



423


424 UMAP for each sequencing batch used (n=3). There were not significant differences

425 observe across sequencing runs

426

427 **Figure S5. Expression of canonical cell-type markers among clusters**

428



429 Canonical lineage specific marker expression confirming identify of proximal airway cell
 430 clusters. Size of dot indexed to percent expressed and color intensity reflects average
 431 scaled expression (deep blue depicting highest expression).
 432

433 **Figure S6. Global Cell Clusters**

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458


459

460

461


462

463



UMAP demonstrating cell types/states present in the proximal airway mucosal scar in iSGS patients. Labels derived from canonical marker expression (Figure S5).

464 **Figure S7: Flow Cytometry Confirming Epithelial Depletion and Immune Cell**
465 **Increase in iSGS Airway Scar.**
466



467
468
469 Representative flow cytometry of fresh single cell suspension from matched iSGS airway
470 scar and healthy mucosa (n=5) confirming depletion of epithelial cells and increase in
471 immune cells within iSGS airway scar when compared to matched healthy control. Cells
472 gated on FSC/SSC, singlets, live cells followed by CD45 (AlexaFlur® 647) and CD326
473 (EpCAM PE/Cy7). Graph depicting % change in cell population for matched scar/healthy
474 mucosa for each of the five individual patients. Bar represents mean, error bars SEM,
475 and dots show individual patients.
476
477

478 **Figure S8: Differentially Expressed Genes (DEG) in Each Cell Cluster**

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509


510

511

512

513

514



Differentially expressed genes (DEG: $P < 0.05$, log fold change $> |1.5|$) depicted for each cell type. Wide variability across the cell types with epithelial cell and fibroblast subsets showing the greatest number of DEG.

515 SUPPLEMENTARY BIBLIOGRAPHY

516

- 517 1 Gelbard, A. *et al.* Causes and consequences of adult laryngotracheal stenosis.
518 *Laryngoscope* **125**, 1137-1143, doi:10.1002/lary.24956 (2015).
- 519 2 Gelbard, A. *et al.* Treatment options in idiopathic subglottic stenosis: protocol for
520 a prospective international multicentre pragmatic trial. *BMJ Open* **8**, e022243,
521 doi:10.1136/bmjopen-2018-022243 (2018).
- 522 3 Barman, M. *et al.* Enteric salmonellosis disrupts the microbial ecology of the
523 murine gastrointestinal tract. *Infect Immun* **76**, 907-915, doi:10.1128/IAI.01432-
524 07 (2008).
- 525 4 Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D.
526 Development of a dual-index sequencing strategy and curation pipeline for
527 analyzing amplicon sequence data on the MiSeq Illumina sequencing platform.
528 *Applied and environmental microbiology* **79**, 5112-5120, doi:10.1128/aem.01043-
529 13 (2013).
- 530 5 Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina
531 amplicon data. *Nat Methods* **13**, 581-583, doi:10.1038/nmeth.3869 (2016).
- 532 6 Caruso, V., Song, X., Asquith, M. & Karstens, L. Performance of Microbiome
533 Sequence Inference Methods in Environments with Varying Biomass. *mSystems* **4**,
534 doi:10.1128/mSystems.00163-18 (2019).
- 535 7 Pruesse, E. *et al.* SILVA: a comprehensive online resource for quality checked and
536 aligned ribosomal RNA sequence data compatible with ARB. *Nucleic acids research*
537 **35**, 7188-7196, doi:10.1093/nar/gkm864 (2007).
- 538 8 Davis, N. M., Proctor, D. M., Holmes, S. P., Relman, D. A. & Callahan, B. J. Simple
539 statistical identification and removal of contaminant sequences in marker-gene
540 and metagenomics data. *Microbiome* **6**, 226, doi:10.1186/s40168-018-0605-2
541 (2018).
- 542 9 McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive
543 analysis and graphics of microbiome census data. *PloS one* **8**, e61217,
544 doi:10.1371/journal.pone.0061217 (2013).
- 545 10 Wickham, H. *ggplot2: elegant graphics for data analysis*. (Springer, 2009).
- 546 11 Hillel, A. T. *et al.* Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis.
547 *mSphere* **4**, doi:10.1128/mSphereDirect.00211-19 (2019).
- 548 12 Marincola Smith, P. *et al.* Colon epithelial cell TGFbeta signaling modulates the
549 expression of tight junction proteins and barrier function in mice. *Am J Physiol*
550 *Gastrointest Liver Physiol* **320**, G936-G957, doi:10.1152/ajpgi.00053.2021 (2021).
- 551 13 Zheng, G. X. *et al.* Massively parallel digital transcriptional profiling of single cells.
552 *Nat Commun* **8**, 14049, doi:10.1038/ncomms14049 (2017).
- 553 14 Liu, Q. *et al.* scRNABatchQC: multi-samples quality control for single cell RNA-seq
554 data. *Bioinformatics* **35**, 5306-5308, doi:10.1093/bioinformatics/btz601 (2019).
- 555 15 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902
556 e1821, doi:10.1016/j.cell.2019.05.031 (2019).

- 557 16 Franzen, O., Gan, L. M. & Bjorkegren, J. L. M. PanglaoDB: a web server for
558 exploration of mouse and human single-cell RNA sequencing data. *Database*
559 (*Oxford*) **2019**, doi:10.1093/database/baz046 (2019).
- 560 17 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
561 differential expression analysis of digital gene expression data. *Bioinformatics* **26**,
562 139-140, doi:10.1093/bioinformatics/btp616 (2010).
- 563 18 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach
564 for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**,
565 15545-15550, doi:10.1073/pnas.0506580102 (2005).
- 566 19 Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set
567 analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res* **47**, W199-W205,
568 doi:10.1093/nar/gkz401 (2019).
- 569 20 Tian, Y. *et al.* Using DGGE profiling to develop a novel culture medium suitable for
570 oral microbial communities. *Mol Oral Microbiol* **25**, 357-367, doi:10.1111/j.2041-
571 1014.2010.00585.x (2010).
- 572 21 RCT., R. F. f. S. C. R: *A Language and Environment for Statistical Computing*. .
573 (2016.).
- 574 22 Oksanen, J. *et al.* vegan: Community Ecology Package. R package version 2.0-10.
575 (2014).
- 576 23 Anderson, M. J. A new method for non-parametric multivariate analysis of
577 variance. *Austral Ecol* **26**, 32-46, doi:10.1111/j.1442-9993.2001.01070.pp.x
578 (2001).
- 579 24 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
580 dispersion for RNA-seq data with DESeq2. *Genome Biology* **15**,
581 doi:10.1186/s13059-014-0550-8 (2014).
- 582 25 McMurdie, P. J. & Holmes, S. Waste not, want not: why rarefying microbiome data
583 is inadmissible. *PLoS computational biology* **10**, e1003531-e1003531,
584 doi:10.1371/journal.pcbi.1003531 (2014).
- 585 26 Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and
586 powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* **57**, 289-
587 300, doi:10.2307/2346101 (1995).
- 588

Figure S1.




Figure S2.





Figure S3.




Figure S4.




Figure S6.





Figure S7.



% Change in Cell Population (Scar vs Matched Healthy)




Figure S8.

